Better Health, Brighter Future
TORONTO, ON July 7, 2020 – As part of its on-going effort and commitment to provide care for Canadian patients, Takeda Canada Inc. is proud to introduce the new OnePath® Patient Support Program. With Takeda’s acquisition of Shire, Takeda Canada has now unified both previous patient programs to create one enterprise Patient Services solution across the organization.
The OnePath® Patient Support Program offers a personalized treatment support plan to each patient. OnePath® Care Managers provide reimbursement navigation, coordinate medication, and offer support with product education and training to ensure patient’s needs are met throughout their treatment journey.
“As patients’ needs continue to evolve, we’re committed to strengthening our programs to meet those needs in a personalized manner,” says Gamze Yüceland, General Manager, Takeda Canada Inc. “OnePath® brings Takeda’s business priorities of Patient, Trust, Reputation, and Business to life, demonstrating our commitment to do what we can to provide better health and a brighter future to Canadians.”
Takeda is committed to a seamless program transition to OnePath® to ensure patients have support at every step of their care journey. If patients have any questions or concerns, they are encouraged to reach out to the OnePath program at 1-844-691-7284 or email [email protected].
Being placed on a new therapy can be confusing and sometimes overwhelming for many Canadians. The patient journey is filled with managing treatment information and lifestyle modifications, ensuring consistent access to care, and the need for empowering support to ensure patients can lead the best quality of life possible. OnePath® is an example of Takeda Canada’s positive and impactful way to deliver effective patient care, with maximum benefits and guidance that leaves patients and caregivers feeling confident in their therapeutic journey.
For more information, please visit www.OnePath.ca.
About Takeda Canada Inc.
Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Additional information about Takeda Canada is available at www.takeda.com/en-ca.
Media Contact:
Amanda Jacobs
[email protected]
+1 647 798 2231